Literature DB >> 10082132

Transforming growth factor-alpha short-circuits downregulation of the epidermal growth factor receptor.

X Ouyang1, T Gulliford, G Huang, R J Epstein.   

Abstract

Transforming growth factor-alpha (TGFalpha) is an epidermal growth factor receptor (EGFR) ligand which is distinguished from EGF by its acid-labile structure and potent transforming function. We recently reported that TGFalpha induces less efficient EGFR heterodimerization and downregulation than does EGF (Gulliford et al., 1997, Oncogene, 15:2219-2223). Here we use isoform-specific EGFR and ErbB2 antibodies to show that the duration of EGFR signalling induced by a single TGFalpha exposure is less than that induced by equimolar EGF. The protein trafficking inhibitor brefeldin A (BFA) reduces the duration of EGF signalling to an extent similar to that seen with TGFalpha alone; the effects of TGFalpha and BFA on EGFR degradation are opposite, however, with TGFalpha sparing EGFR from downregulation but BFA accelerating EGF-dependent receptor loss. This suggests that BFA blocks EGFR recycling and thus shortens EGF-dependent receptor signalling, whereas TGFalpha shortens receptor signalling and thus blocks EGFR downregulation. Consistent with this, repeated application of TGFalpha is accompanied by prolonged EGFR expression and signalling, whereas similar application of EGF causes receptor downregulation and signal termination. These findings indicate that constitutive secretion of pH-labile TGFalpha may perpetuate EGFR signalling by permitting early oligomer dissociation and dephosphorylation within acidic endosomes, thereby extinguishing a phosphotyrosine-based downregulation signal and creating an irreversible autocrine growth loop.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10082132     DOI: 10.1002/(SICI)1097-4652(199904)179:1<52::AID-JCP7>3.0.CO;2-M

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  9 in total

1.  Endosomal receptor kinetics determine the stability of intracellular growth factor signalling complexes.

Authors:  A Rami Tzafriri; Elazer R Edelman
Journal:  Biochem J       Date:  2007-03-15       Impact factor: 3.857

2.  MYO1D binds with kinase domain of the EGFR family to anchor them to plasma membrane before their activation and contributes carcinogenesis.

Authors:  Yoo-Seung Ko; Jeong A Bae; Keon Young Kim; Sung Jin Kim; Eun Gene Sun; Kyung Hwa Lee; Nacksung Kim; Hyuno Kang; Young-Woo Seo; Hangun Kim; Ik Joo Chung; Kyung Keun Kim
Journal:  Oncogene       Date:  2019-08-16       Impact factor: 9.867

3.  Where EGF receptors transmit their signals.

Authors:  Nancy L Lill; Nurettin Ilter Sever
Journal:  Sci Signal       Date:  2012-09-25       Impact factor: 8.192

4.  Association of ErbB2 Ser1113 phosphorylation with epidermal growth factor receptor co-expression and poor prognosis in human breast cancer.

Authors:  X Ouyang; T Gulliford; H Zhang; G Smith; G Huang; R J Epstein
Journal:  Mol Cell Biochem       Date:  2001-02       Impact factor: 3.396

Review 5.  Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy.

Authors:  P Nagy; A Jenei; S Damjanovich; T M Jovin; J Szölôsi
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

Review 6.  ErbB receptor negative regulatory mechanisms: implications in cancer.

Authors:  Colleen Sweeney; Jamie K Miller; David L Shattuck; Kermit L Carraway
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

Review 7.  Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases.

Authors:  Bhopal Mohapatra; Gulzar Ahmad; Scott Nadeau; Neha Zutshi; Wei An; Sarah Scheffe; Lin Dong; Dan Feng; Benjamin Goetz; Priyanka Arya; Tameka A Bailey; Nicholas Palermo; Gloria E O Borgstahl; Amarnath Natarajan; Srikumar M Raja; Mayumi Naramura; Vimla Band; Hamid Band
Journal:  Biochim Biophys Acta       Date:  2012-10-17

8.  Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells.

Authors:  G C Huang; S Hobbs; M Walton; R J Epstein
Journal:  Br J Cancer       Date:  2002-04-08       Impact factor: 7.640

9.  HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo.

Authors:  Laurence Booth; Jane L Roberts; Andrew Poklepovic; Francesca Avogadri-Connors; Richard E Cutler; Alshad S Lalani; Paul Dent
Journal:  Oncotarget       Date:  2017-10-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.